| Sign In to gain access to subscriptions and/or personal tools. |
Win 55212-2, a cannabinoid receptor agonist, attenuates leukocyte/endothelial interactions in an experimental autoimmune encephalomyelitis modelDepartment of Physiology, Temple University, 3420 N. Broad Street, Philadelphia, PA 19140, USA
Center for Substance Abuse Research and Department of Pharmacology, Temple University, Philadelphia, PA 19140, USA
Wyeth/Genetics Institute, Inc, Discovery Research, Immunology and Hemostasis, Cambridge, MA 01810, USA
Center for Substance Abuse Research and Department of Microbiology and Immunology, Temple University, Philadelphia, PA 19140, USA
Center for Substance Abuse Research and Department of Pharmacology, Temple University, Philadelphia, PA 19140, USA
Department of Physiology, Temple University, 3420 N. Broad Street, Philadelphia, PA 19140, USA, ronald.tuma{at}temple.edu Multiple sclerosis (MS) is the most common of the immune demyelinating disorders of the central nervous system (C NS). Leukocyte/endothelial interactions are important steps in the progression of the disease and substances that interfere with these activities have been evaluated as potential therapeutic agents. C annabinoid receptor agonists have been shown to downregulate immune responses and there is preliminary evidence that they may slow the progress of MS. The purpo se of this investigation was to determine how cannabinoid recepto r agonists interfere with leukocyte rolling and adhesion. This was investigated in an experimental autoimmune encephalo myelitis (EAE) model using six to eight week old C 57BL/6 mice. Mouse myelin oligodendrocyte protein and pertussis toxin were used to induce EAE. WIN 55212-2, C B1 and C B2 antagonist were given. By use of in vivo intravital microscopy, leukocyte/endothelial interactio ns were evaluated via a cranial window implanted two days before. The results demonstrated that EAE increases leukocyte rolling and firm adhesion in the brain, and that this increased leukocyte/endothelial interactio n can be attenuated by administration of WIN 55212-2. Furthermore, use of the selective antagonists for the C B1 recepto r (SR 141716A) and the C B2 receptor (SR144528) in this study demonstrated that the cannabinoid’s inhibitory effects on leukocyte/endothelial interactions can be mediated by activating C B2 receptor.
Key Words: cannabinoid • cannabinoid receptor 1 and 2 • experimental autoimmune encephalomyelitis • leukocyte/endothelial interaction • multiple sclerosis
Multiple Sclerosis, Vol. 10, No. 2,
158-164 (2004) This article has been cited by other articles:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
|
 |
Sign In to gain access to subscriptions and/or personal tools.
